Serina Therapeutics, Inc.宣布,针对其研究项目第一队列的盲态安全性及耐受性数据评估预计将于2026年第三季度完成。评估结束后,公司计划推进至第二队列的研究阶段。这一进展标志着项目按既定时间表顺利推进。
Serina Therapeutics, Inc.宣布,针对其研究项目第一队列的盲态安全性及耐受性数据评估预计将于2026年第三季度完成。评估结束后,公司计划推进至第二队列的研究阶段。这一进展标志着项目按既定时间表顺利推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.